These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 4474966)
1. The clinical significance of highly purified pig-insulin preparations. Deckert T; Andersen OO; Poulsen JE Diabetologia; 1974 Dec; 10(6):703-8. PubMed ID: 4474966 [No Abstract] [Full Text] [Related]
2. Treatment of insulin lipoatrophy with monocomponent insulin. Teuscher A Diabetologia; 1974 Jun; 10(3):211-4. PubMed ID: 4845721 [No Abstract] [Full Text] [Related]
3. Intermediate-acting insulin preparations: NPH and lente. Deckert T Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of insulin-binding antibodies in diabetic patients treated with monocomponent insulin. Czyzyk A; Lawecki J; Rogala H; Miedzińska E; Popik-Hankiewicz A Diabetologia; 1974 Jun; 10(3):233-6. PubMed ID: 4845724 [No Abstract] [Full Text] [Related]
5. [Proinsulin and a-component antibodies in diabetics treated with monocomponent and conventional insulin]. Gamba S; Barbero PL; Bollati C; Castellazzi R; D'Adda A; Bruni B Minerva Dietol Gastroenterol; 1979; 25(3):309-14. PubMed ID: 400003 [No Abstract] [Full Text] [Related]
6. Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment. Bruni B; Gamba S; Regis G; Turco GL Diabetologia; 1978 Mar; 14(3):165-9. PubMed ID: 566232 [TBL] [Abstract][Full Text] [Related]
7. Circulating IgG antibody to protamine in patients treated with protamine-insulins. Kurtz AB; Gray RS; Markanday S; Nabarro JD Diabetologia; 1983 Oct; 25(4):322-4. PubMed ID: 6196244 [TBL] [Abstract][Full Text] [Related]
8. The future of basal insulin. Shah VN; Moser EG; Blau A; Dhingra M; Garg SK Diabetes Technol Ther; 2013 Sep; 15(9):727-32. PubMed ID: 23965036 [No Abstract] [Full Text] [Related]
9. [Experience of using biosulin P and biosulin H for the treatment of diabetes mellitus]. Dedov II; Balabolkin MI Ter Arkh; 2004; 76(1):65-8. PubMed ID: 15108443 [No Abstract] [Full Text] [Related]
10. [Is proinsulin contamination of commercial insulin preparations responsible for the stimulation of insulin antibodies?]. Kerp L; Steinhilber S; Kasemir H Klin Wochenschr; 1970 Jul; 48(14):884-5. PubMed ID: 5535446 [No Abstract] [Full Text] [Related]
11. Newer basal insulin analogues: degludec, detemir, glargine. Kalra S J Pak Med Assoc; 2013 Nov; 63(11):1442-4. PubMed ID: 24392539 [No Abstract] [Full Text] [Related]
12. U-500 insulin in the treatment of antibody-mediated insulin resistance. Nathan DM; Axelrod L; Flier JS; Carr DB Ann Intern Med; 1981 May; 94(5):653-6. PubMed ID: 7015948 [TBL] [Abstract][Full Text] [Related]
13. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies. Anderson OO Acta Endocrinol (Copenh); 1975 Apr; 78(4):723-35. PubMed ID: 1173962 [TBL] [Abstract][Full Text] [Related]
14. [Immunogenicity of MC Lente Novo insulin]. Rogala H; Lawecki J; Czyzyk A Pol Arch Med Wewn; 1986 Sep; 76(3):172-6. PubMed ID: 3554163 [No Abstract] [Full Text] [Related]
15. [The place of "monocomponent" insulins in diabetes mellitus therapy]. Teuscher A Schweiz Med Wochenschr; 1975 Apr; 105(16):485-94. PubMed ID: 1215860 [TBL] [Abstract][Full Text] [Related]
16. Human insulin. Roberts RJ Iowa Med; 1984 Mar; 74(3):116-8. PubMed ID: 6373658 [No Abstract] [Full Text] [Related]
18. A method for the determination of plasma insulin antibodies and its application in normal and diabetic subjects. Sebriakova M; Little JA Diabetes; 1973 Jan; 22(1):30-40. PubMed ID: 4734254 [No Abstract] [Full Text] [Related]
19. [KH metabolic pattern and insulin antibody level during treatment of diabetes mellitus with conventional and/or prepurified insulin preparations]. Göbel P; Kramer W; Heni F Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1426-9. PubMed ID: 611859 [No Abstract] [Full Text] [Related]